公司代码：600200 公司简称：江苏吴中 2020 年半年度报告 江苏吴中实业股份有限公司 2020 年半年度报告 2020 年 8 月 26 日 1 / 161 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人钱群山、钱群英、主管会计工作负责人孙曦及会计机构负责人（会计主管人员） 钟素芳声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 本报告期内，公司未提出报告期利润分配预案或公积金转增股本事宜。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本报告中描述了公司可能存在的风险， ...

2020 年第一季度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2020 年第一季度报告 2020 年 4 月 28 日 1 / 24 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 24 2020 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人钱群山、钱群英、主管会计工作负责人孙曦及会计机构负责人（会计主管人员） 钟素芳保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元币种：人民币 | --- | --- | --- | --- | --- | |--------------------------------------- ...

Financial Performance - The company achieved a consolidated net profit of ¥64,533,748.49 for the year 2019, with the parent company's net profit at ¥105,108,521.60[7] - The parent company started the year with an undistributed profit of -¥203,117,689.42 and ended the year with an undistributed profit of -¥98,009,167.82[7] - The company will not distribute profits for 2019 due to negative retained earnings from the previous year[7] - The company's operating revenue for 2019 was CNY 2,109,850,652.89, representing a 23.99% increase compared to CNY 1,701,627,607.60 in 2018[25] - The net profit attributable to shareholders for 2019 was CNY 64,533,748.49, a significant recovery from a loss of CNY 285,568,326.57 in 2018[25] - The basic earnings per share for 2019 was CNY 0.090, compared to a loss of CNY 0.396 in 2018[25] - The company reported a gross profit of CNY 624,569,200, which is a 3.50% increase from the previous year[64] - The company reported a net profit attributable to the parent company of CNY 64,533,700, an increase of CNY 35,010,210 compared to the previous year[64] Share Repurchase and Investments - A total of ¥40,042,190 was used for share repurchase, completed on December 27, 2019[7] - The company reported a significant investment income of ¥5,103.18 million from the repurchase and cancellation of shares related to unfulfilled performance commitments[84] Operational Highlights - The net cash flow from operating activities decreased by 149.70% to -CNY 166,027,875.30 in 2019, down from CNY 334,027,632.20 in 2018[25] - The company completed the divestiture of its real estate business to focus on its core pharmaceutical industry, enhancing its strategic direction[34] - The company has established a new "Respiratory Division" to enhance the development and academic promotion of antiviral products, particularly focusing on Abidol[52] - The company has over 30 ongoing research projects and has been granted 33 effective patents, including 30 invention patents[52] Industry and Market Conditions - The pharmaceutical manufacturing industry is experiencing a slowdown in growth due to supply-side reforms and stricter environmental regulations, leading to the exit of outdated production capacities from the market[106] - The biopharmaceutical sector in China has developed a complete industrial chain and is entering a phase of large-scale industrialization, supported by increasing national policy backing for R&D investments[107] - The pharmaceutical industry is experiencing increased competition and consolidation due to policies like volume-based procurement, impacting market dynamics[199] Research and Development - The company has invested over 500 million yuan raised from its IPO in 2015 into R&D, production, and sales, which is gradually showing positive results[108] - The company has undertaken 8 national-level and 17 provincial-level science and technology projects, enhancing its innovation capabilities[52] - The company reported a total R&D investment of 4,709.95 million RMB, accounting for 3.11% of operating revenue[126] - The company has initiated clinical research for its sustained-release tablets of Trimetazidine Hydrochloride, which is currently under development[37] Sales and Marketing - The company reported a total sales expense of 465,976,948.57 RMB, which represents 30.76% of its revenue, an increase of 13.94% compared to the previous year[150] - The revenue distribution by customer type shows that 40.03% comes from hospitals, while 10.29% is from retail sales[143] - The company actively participates in provincial centralized drug procurement, adhering to competitive bidding prices for its major products[147] Challenges and Risks - The company is currently facing operational risks due to the impact of environmental regulations and market conditions, which may lead to a reduction in market share[158] - The impact of policies such as "4+7 centralized procurement" and medical insurance cost control may lead to a decline in drug prices, potentially affecting profitability[148] Strategic Focus - The company is focusing on optimizing R&D, quality, and sales to enhance its competitiveness and expand its market presence[200] - The company is committed to improving internal controls and production quality to navigate the evolving regulatory landscape and competitive pressures[108]

2019 年第三季度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2019 年第三季度报告 2019 年 10 月 25 日 1 / 29 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 29 2019 年第三季度报告 单位：元币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人赵唯一、王小刚，主管会计工作负责人孙曦及会计机构负责人（会计主管人员） 钟素芳保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|----------------------------------|-------------- ...

2019 年半年度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 陈颐 | 工作原因 | 王小刚 | 三、 本半年度报告未经审计。 四、 公司负责人赵唯一、王小刚，主管会计工作负责人孙曦及会计机构负责人（会计主管人员） 钟素芳声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 本报告期内，公司未提出报告期利润分配预案或公积金转增股本事宜。 2019 年 8 月 21 日 1 / 148 2019 年半年度报告 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七 ...

2019 年第一季度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2019 年第一季度报告 2019 年 4 月 29 日 1 / 25 2019 年第一季度报告 í 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 25 2019 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人赵唯一、王小刚，主管会计工作负责人孙曦及会计机构负责人（会计主管人员） 钟素芳保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |--------------------------------------------- ...

Financial Performance - In 2018, the company reported a consolidated net profit of -285,568,326.57 yuan, with the parent company's net profit at -247,011,914.23 yuan[7]. - The parent company had an undistributed profit at the beginning of the year of 84,320,174.46 yuan, ending the year with an undistributed profit of -203,117,689.42 yuan[7]. - The company did not distribute profits for the year 2018 due to the reported losses[7]. - The company's operating revenue for 2018 was CNY 1,701,627,607.60, a decrease of 42.52% compared to the previous year[23]. - The net profit attributable to shareholders was a loss of CNY 285,568,326.57, representing a decline of 314.54% year-on-year[23]. - The company reported a basic earnings per share of -CNY 0.396, down 314.05% from CNY 0.185 in 2017[23]. - The total assets at the end of 2018 were CNY 4,617,910,901.74, a slight decrease of 0.36% from the previous year[23]. - The company achieved operating revenue of CNY 1,701.63 million, a decrease of 42.52% compared to the previous year, with main business revenue dropping by 42.63%[69]. - The company reported a net profit attributable to the parent company of CNY -285.57 million, a decline of 314.54% year-on-year[69]. Industry and Market Analysis - The company has indicated that there are industry risks that may affect future performance, as discussed in the operational analysis section of the report[9]. - In 2018, the pharmaceutical manufacturing industry reported a total revenue of 239.86 billion yuan, reflecting the impact of medical insurance cost control and price reduction policies[38]. - The dye industry faced supply tightness due to environmental pressures, leading to sustained high prices for dyes throughout 2018[42]. - The national average residential price index reached 14,678 yuan per square meter in 2018, with a year-on-year increase of 5.09%[44]. - The biopharmaceutical industry in China has been steadily increasing in profitability since the 1980s, becoming one of the fastest-growing and most profitable sectors in the pharmaceutical industry[108]. - By 2020, China's biopharmaceutical market is projected to become the second largest globally, following the United States, according to IMS Health[112]. - The chemical drug formulation sector remains dominant in China's pharmaceutical market, with generics still leading while self-developed drugs are on the rise[114]. - The chemical raw material drug industry in China has shown signs of recovery in recent years, driven by new domestic medical reform policies and stricter industry regulations[116]. Research and Development - The company has over 30 ongoing research projects in the pharmaceutical sector and holds 28 effective patents, including 25 invention patents[49]. - The company is committed to enhancing its R&D capabilities and has plans for team expansion and investment in new technologies and products post-acquisition[49]. - The total R&D investment for the year 2018 amounted to CNY 40,414,843.77, representing 2.38% of total operating revenue[85]. - The company capitalized 33.29% of its R&D expenditures, with CNY 13,455,910.52 being capitalized[85]. - The company’s R&D personnel accounted for 11% of the total workforce, with 197 employees dedicated to R&D[85]. - The company has a total of 7,533.73 million RMB in cumulative R&D investment for its major projects[140]. - The company is actively pursuing consistency evaluations for several products, including Trimetazidine sustained-release tablets and Lansoprazole injection[140]. Product and Segment Performance - The pharmaceutical segment achieved a total revenue of CNY 1,309.60 million, an increase of CNY 146.06 million, or 12.55% year-on-year[57]. - The gross profit for the pharmaceutical segment was CNY 504.57 million, up CNY 77.37 million, or 18.11% compared to the previous year[57]. - The chemical segment reported a revenue of CNY 238.54 million, a significant decline of CNY 410.62 million, or 63.25% year-on-year due to environmental regulations[63]. - The gross profit for the chemical segment decreased to CNY 59.27 million, down CNY 114.66 million, or 65.92% year-on-year[63]. - The real estate sector reported revenue of CNY 128.79 million, a decline of 64.27%, with a gross margin of 15.87%, an increase of 10.42 percentage points[70]. - The company’s main business in the pharmaceutical sector generated revenue of CNY 1,309.60 million, an increase of 12.55%, with a gross margin of 38.53%, up by 1.81 percentage points[70]. Compliance and Environmental Initiatives - The company is actively pursuing environmental remediation and has developed a detailed rectification plan to ensure compliance with safety and environmental standards[65]. - The company is focusing on technological advancements in environmental protection and has initiated a transition towards cleaner production methods[66]. - The company has invested heavily in environmental protection equipment and technology to comply with stricter national safety and environmental standards[171]. - The company emphasizes process management and environmental safety, implementing a long-term mechanism for efficiency and compliance with national standards[186]. Sales and Marketing Strategies - The sales model remains unchanged, primarily utilizing terminal sales, distribution, and OTC models, with hospitals accounting for 48.17% of total revenue[151][154]. - The increase in sales expenses is primarily due to expanded marketing expenditures aimed at developing the pharmaceutical business market[167]. - Sales expenses for the pharmaceutical business amounted to RMB 408.96 million, an increase of 41.71% compared to the previous year, accounting for 31.23% of operating income[167]. Strategic Initiatives - The company has established a wholly-owned subsidiary to enhance its investment capabilities in the pharmaceutical sector, aiming for strategic acquisitions and partnerships[66]. - The company has established a technology center and has a research team of over 50 personnel, accounting for more than 10% of total employees, with 3 provincial high-tech products developed[177]. - The company has established a complete industrial chain covering gene drugs, chemical drugs, and modern traditional Chinese medicine, with a diverse range of production lines[117]. - The company is implementing measures to enhance production processes, product quality, and sales channels to mitigate the impact of these challenges[117].

2018 年 10 月 29 日 1 / 25 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 12 | 2018 年第三季度报告 2018 年第三季度报告 一、 重要提示 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2018 年第三季度报告 | 股东总数（户） | | | | | | 70,976 | | --- | --- | --- | --- | --- | --- | --- | | | | | 前十名股东持股情况 | | | | | 股东名称 | 期末持股数量 | 比例 | 持有有限售条 | 质押或冻结情况 | | 股东性质 | | （全称） | | (%) | 件股份数量 | 股份状态 | 数量 | | | 苏州吴中投资 | 122,795,762 | 17.01 | 0 | 质押 | 55,000,000 | 境内非国有 | | 控股有限公司 | | | | | | 法人 | | 毕红芬 | 12,413,238 ...

2018 年半年度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2018 年半年度报告 2018 年 8 月 20 日 1 / 158 2018 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 本报告期内，公司未提出报告期利润分配预案或公积金转增股本事宜。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本报告中描述了公司可能存在的风险，敬请查阅第四节"经营情况的讨论与分析" 中"可能面对的风险"的相关内容。 十、 其他 □适用 √不适用 2 / 158 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人赵唯一、王 ...

2018 年第一季度报告 公司代码：600200 公司简称：江苏吴中 江苏吴中实业股份有限公司 2018 年第一季度报告 2018 年 4 月 27 日 1 / 17 | 一、重要提示 3 | | --- | | 二、公司基本情况 3 | | 三、重要事项 5 | | 四、附录 7 | 2018 年第一季度报告 一、 重要提示 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | -127,803.99 | | 3 / 17 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增减(%) 总资产 4,691,221,551.61 4,634,581,387.80 1.22 归属于上市公司股 东的净资产 2,939,727,186.90 2,919,630,587.98 0.69 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现 金流量净额 92,177,948.23 -40 ...